首页 › 基金 › ACORN CAPITAL ADVISORS, LLC › TRVI
ACORN CAPITAL ADVISORS, LLC 对 TRVI 的持仓历史
TREVI THERAPEUTICS INC · 医疗保健
ACORN CAPITAL ADVISORS, LLC 在 Q3 2026 的 13F 申报中披露持有 TRVI(TREVI THERAPEUTICS INC)2,144,844 股,市值约 US$30.7M,约占其申报组合的 8.44%,在其申报持仓中市值排名第 5 位。 ACORN CAPITAL ADVISORS, LLC 最近 8 个申报季度中有 8 个季度披露了 TRVI 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
ACORN CAPITAL ADVISORS, LLC 对 TRVI 的持仓演变
ACORN CAPITAL ADVISORS, LLC 于 Q4 2024 首次披露 TRVI 持仓:2,001,048 股(约 US$8.2M)。 该持仓在 Q2 2026 达到峰值 2,144,844 股,市值约 US$40.0M。 在 8 次申报中,ACORN CAPITAL ADVISORS, LLC 1 次增持、0 次减持、6 次保持不变。 最近一期申报(Q3 2026)显示持股 2,144,844 股、市值约 US$30.7M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 2.00M | $8.24M | 新进 |
| Q1 2025 | 2.14M | $13.49M | 增持 |
| Q2 2025 | 2.14M | $11.73M | 持有 |
| Q3 2025 | 2.14M | $19.63M | 持有 |
| Q4 2025 | 2.14M | $26.85M | 持有 |
| Q1 2026 | 2.14M | $25.59M | 持有 |
| Q2 2026 | 2.14M | $40.00M | 持有 |
| Q3 2026 | 2.14M | $30.71M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TRVI 与 13F 数据
TRVI(TREVI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 58 只申报持有 TRVI,申报仓位最大的包括:NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$60.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TRVI 的基金
- NEA Management Company, LLC 13.22M 股 · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M 股 · $185.37M · Q2 2026
- Vivo Capital, LLC 4.23M 股 · $60.57M · Q3 2026
- Vestal Point Capital, LP 3.10M 股 · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M 股 · $57.32M · Q2 2026
- First Light Asset Management, LLC 2.10M 股 · $39.11M · Q2 2026
- Artia Global Partners LP 2.21M 股 · $31.66M · Q3 2026
- ORBIMED ADVISORS LLC 1.43M 股 · $26.67M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M 股 · $25.78M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M 股 · $24.96M · Q3 2026
- Saturn V Capital Management LP 1.57M 股 · $22.54M · Q3 2026
- Soleus Capital Management, L.P. 1.18M 股 · $22.00M · Q2 2026
更多关于 ACORN CAPITAL ADVISORS, LLC
常见问题
How long has ACORN CAPITAL ADVISORS, LLC held TRVI?
ACORN CAPITAL ADVISORS, LLC has disclosed TRVI holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is ACORN CAPITAL ADVISORS, LLC's current position in TRVI?
As of Q3 2026, ACORN CAPITAL ADVISORS, LLC holds 2.14M shares of TRVI (TREVI THERAPEUTICS INC), valued at $30.71M, representing 8.44% of its reported portfolio and ranking #5.
Has ACORN CAPITAL ADVISORS, LLC been buying or selling TRVI?
In the latest 13F filing (Q3 2026), ACORN CAPITAL ADVISORS, LLC held unchanged its position in TRVI. The position peaked in Q2 2026 at 2.14M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 58 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.